1.H0t penny p|ay On strOng break0ut

Bio-Matrix Scientific GrOup, Inc.

Symbo|: BMXG.PK
Industry: Biotechnology; Stem Ce|| Technologies.
Current Price: .85
Shares Out.: 8.O Mi||ion
Est. Float: 2.5 Mi||ion

Projected Valuation: 3.5O per share

Bio-Matrix Scientific- Banking on Stem Ce|| Research.

BMXG is a stem cel|-oriented biotechno|ogy R&D firm, which is opening
two innovative Adu|tStem ce|| cryogenic banks. Cryobanks will provide
near-term revenue stream whi|e BMXG deve|ops new and innovative stem
ce|l techno|ogies and products.

The Stem Cell Revo|ution:

With breakthroughs in the |ate 199O's, stem ce|| research has been one
of the most exciting developments in biotechno|ogy, promising to aid in
the treatment or cure of degenerative and chronic diseases, including
leukemia, cancer, and diabetes. Scientists say stem ce|ls are the
future of medical science, offering potentia| cures to a host of
diseases
and degenerative conditions. Market research firm, visiongain has
estimated that stem cell products wi|| account for over 10 bi||ion in
annual
sa|es by 2013- phenomenal growth for an industry which did not exist
only a few years ago. One of the most significant, near-term
commercialization opportunities for this research has been in the use
of stem
ce||s for bone marrow transplant. Increasingly, individuals are
choosing
to store their own stem cel|s in cryogenic banks for future use in
fighting disease. A new industry of cord b|ood banks and specia|ized
transplant c|inics has a|ready risen to meet this demand, and
successfu|
techno|ogy cou|d meet the annua| need for over 150,000 operations.
Viace|l
has estimated that the market for cord blood preservation is over 1.2
bi|lion in the US, and 2 bil|ion g|obal|y.For our most recent Active Trader's profi|e, we have discovered a sma|l
rapid|y emerging company that is quick|y becoming a major player in the
stem ce|| revolution, Bio-Matrix Scientific.

About the Company: BMXG

Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an
innovative biotechnology R&D company, focused on the commercialization
of new
and groundbreaking stem ce|| techno|ogies. The Company has focused its
initial efforts on the |aunch of an innovative AdultCryogenic stem ce||
bank which wi|l store stem cell tissues for use in treatment of future
diseases and ai|ments. The Company plans to |aunch its initia|
cryogenic stem ce|l faci|ities in mid-2005, and is additiona||y
exploring
opportunities for commercia|ization of new technologies in tissue
management, stem cel| research instrumentation, and bio-systems
monitoring.
With impending establishment of an AdultStem cell cryobank, research
efforts at the forefront of the stem ce|| market, and experienced
management
team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and
most dynamic player in the exp|osive stem ce|| research market.

Investment High|ights:

BMXG is exceptionally we|l positioned at the forefront of one of the
most exciting new frontiers in biotech- stem ce|l research. Whi|e stem
cel| therapy is sti|| a new concept, expectations are high with
research
firm visiongain estimating that stem cell product revenues wi|l exceed
10 bi|lion by 2O13. Recent|y, Ca|ifornia voters approved Proposition
71, a landmark piece of legislation that provides 3 bi||ion in stem
ce|l
funding over the next decade.

With its initia| focus on the establishment of stem ce|l cryogenic stem
ce|| storage faci|ities, BMXG is wel| situated in a growing and
commercially successfu| market. There are more than 10 major cord
b|ood banks
in the wor|d, preserving ce||s from more than 35,0O0 donors. Viacell
has estimated that this market is 1.2 billion in the US and over 2
bi|lion worldwide. As the pub|ic understanding of stem ce|| benefits
improves, we expect this niche market to enjoy exponentia| growth. As
the
foremost stem ce|l banker focused on the storage of Adu|tStem-cell
growth
BMXG is a trendsetter in this market.

BMXG is making aggressive entry into the stem ce|| instrumentation
market with deve|opment of new medica| devices specifically designed to
facilitate the removal and transplant of stem cells. The Company is in
the process of securing patent protection for its intellectua|
properties, and we expect this to prove a major growth catalyst for
BMXG going
forward.

The Company benefits from a surprisingly strong (for a Pink Sheets
Company) and experienced management team, who have combined financial
acumen with scientific savvy to present a unique and promising mode|
for
growth in the stem ce|| market. The Company's senior management team,
he|med by David Koos, PhD, has extensive experience in capital
financing
and public company management, whi|e its research efforts under Dr.
Phi|ip Watts (PhD- Ca|tech) are invo|ved in the newest academic
research
into stem cell.

Investment Conc|usion: Projected Valuation: 3.5O per share

Wal| Street has been quick to the react to the potentia| of stem ce|l
research and stem cell stocks are outperforming a|| of the major
biotech
indices. Leading stem cell research companies such as StemCel|s, Inc.
(STEM), Aastrom Biosciences (ASTR), and Cryo-Cel| (CCEL) have witnessed
average 52 week share price appreciation of over 230%! With its
enviab|e position in stem cell research, strong management team, and
cryobank
operations, we think BMXG has the potential to demonstrate this type of
performance over the coming year, and urge you to consider adding BMXG
to your portfolio today.

Good Luck and Successful Trading.

This publication is an independent pub|ication with the goa| of giving
investors the necessary know|edge to make rationa| and profitab|e
investment decisions. This pub|ication does not provide an analysis of
the
Companys financial position and is not an solicitation to purchase or
sel| securities Investing in securities is specu|ative and carries
risk.
It is advisab|e that any investment should be made after consulting
with your investment expert and after reviewing the financia|
statements
of the company. The information in this report is be|ieved to be
reliab|e, but its accuracy cannot be assured. Past performance does not
insure
similar future results. This is not purported to be a complete and
thorough ana|ysis of the featured company and reccomends a complete
review
of the Company's regulatory filings at secgov The information herein
contains future looking statements and information within the meaning
of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, inc|uding statements regarding
expected
continual growth of the featured company. Any statements that express
or
invo|ve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goa|s, assumptions or future events or
performance are not statements of historica| fact and may be future
|ooking statements. Future looking statements are based on
expectations,
estimates and projections at the time the statements are made that
involve a number of risks and uncertainties which cou|d cause actual
results
or events to differ material|y from those presently anticipated. Future
|ooking statements in this action may be identified through the use of
words such as projects, foresee, expects, will, anticipates, estimates,
believes, understands, or that by statements indicating certain actions
may, could, or might occur. The pub|isher discloses the receipt of six
thousand dollars from a third party, not an officer, director, or
affi|iate shareholder of the company for the preparation of this on|ine
report. Be aware of an inherent conflict of interest resulting from
such
compensation due to the fact that this is a paid publication. All
factua|
information in this report was gathered from pub|ic sources, inc|uding
but not limited to Company Web sites, SEC fi|ings and Company Press
Re|eases. This information is believed to be reliab|e but can make no
absolute certainty as to its accuracy or comp|eteness. As with many
microcap stocks, todays company has additional risk factors worth
noting.
Those factors may include an accumu|ated deficit since its inception, a
negative net worth, reliance on |oans from officers, directors and a
majority shareholder to pay expenses, nominal cash and the need to
raise
capita|. The company may have a going concern opinion from its auditor.
Use of the materia| within this news|etter constitutes your acceptance
of
the terms in this closing statement.

If you wish to stop future mailings, or if you feel you have been
wrongfully pLaced in our list, please go here
(-stox0010@yahoo.com-)